Postmarketing Surveillance Registry to Monitor Everolimus-eluting Bioresorbable Vascular Scaffold Following Rotational Atherectomy for the Treatment of Complex Coronary Lesions - The ASSURE ROT Registry
Phase of Trial: Phase IV
Latest Information Update: 04 Aug 2017
Price : $35 *
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms ASSURE ROT
- 06 Sep 2013 New trial record
- 30 Aug 2013 Planned End Date changed from 1 Sep 2017 to 1 Aug 2017 according to ClinicalTrials.gov.
- 30 Aug 2013 Status changed from not yet recruiting to recruiting according to ClinicalTrials.gov.